Cargando…

Beyond Undetectable: Modeling the Clinical Benefit of Improved Antiretroviral Adherence in Persons With Human Immunodeficiency Virus With Virologic Suppression

BACKGROUND: Incomplete antiretroviral therapy (ART) adherence has been linked to deleterious immunologic, inflammatory, and clinical consequences, even among virally suppressed (<50 copies/mL) persons with human immunodeficiency virus (PWH). The impact of improving adherence in the risk of severe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castillo-Mancilla, Jose R, Morrow, Mary, Hunt, Peter W, Schnittman, Samuel R, Phillips, Andrew N, Baker, Jason V, Haberer, Jessica E, Janeiro, Maria Joao, Aragao, Filipa, Cohen, Cal, Musinguzi, Nicholas, Brown, Todd T, Cavassini, Matthias, Glass, Tracy R, Serrano-Villar, Sergio, Mawhinney, Samantha, Siedner, Mark
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Major Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10199113/ https://www.ncbi.nlm.nih.gov/pubmed/37213424 http://dx.doi.org/10.1093/ofid/ofad230

Ejemplares similares

Association of Incomplete Adherence to Antiretroviral Therapy With Cardiovascular Events and Mortality in Virologically Suppressed Persons With HIV: The Swiss HIV Cohort Study
por: Castillo-Mancilla, Jose R, et al.
Publicado: (2021)

Income Inequality Is Associated With Low Cumulative Antiretroviral Adherence in Persons With Human Immunodeficiency Virus
por: Vernon, Frances, et al.
Publicado: (2020)

Timing of Antiretroviral Therapy and Systemic Inflammation in Sub-Saharan Africa: Results From the META Longitudinal Cohort Study
por: Siedner, Mark J, et al.
Publicado: (2019)

A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy
por: O’Brien, Meagan P., et al.
Publicado: (2017)

The Presence of Human Immunodeficiency Virus-Associated Neurocognitive Disorders Is Associated With a Lower Adherence to Combined Antiretroviral Treatment
por: Kamal, Susan, et al.
Publicado: (2017)

Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens
por: De La Cruz, Justin, et al.
Publicado: (2019)

Human Immunodeficiency Virus Viral Load Monitoring and Rate of Virologic Suppression Among Patients Receiving Antiretroviral Therapy in Democratic Republic of the Congo, 2013–2020
por: Mayasi Ngongo, Nadine, et al.
Publicado: (2023)

High Rates of Virological Suppression in a Cohort of Human Immunodeficiency Virus-Positive Adults Receiving Antiretroviral Therapy in Ethiopian Health Centers Irrespective of Concomitant Tuberculosis
por: Reepalu, Anton, et al.
Publicado: (2014)

Evaluating HIV Viral Rebound Among Persons on Suppressive Antiretroviral Treatment in the Era of “Undetectable Equals Untransmittable (U = U)”
por: Min, Sugi, et al.
Publicado: (2020)

Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study
por: Elzi, Luigia, et al.
Publicado: (2016)

A Single Quantifiable Viral Load Is Predictive of Virological Failure in Human Immunodeficiency Virus (HIV)-Infected Patients on Combination Antiretroviral Therapy: The Austrian HIV Cohort Study
por: Leierer, Gisela, et al.
Publicado: (2016)

Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral Therapy
por: Bhagwat, Priya, et al.
Publicado: (2019)

Virological Failure and Acquired Genotypic Resistance Associated With Contemporary Antiretroviral Treatment Regimens
por: Rhee, Soo-Yon, et al.
Publicado: (2020)

A Randomized Switch From Nevirapine-Based Antiretroviral Therapy to Single Tablet Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in Virologically Suppressed Human Immunodeficiency Virus-1-Infected Rwandans
por: Collins, Sean E., et al.
Publicado: (2016)

Immune Activation in Primary Human Immunodeficiency Virus: Influence of Duration of Infection, Treatment, and Substance Use
por: Gilada, Trupti, et al.
Publicado: (2022)

Understanding the Risk of Human Immunodeficiency Virus (HIV) Virologic Failure in the Era of Undetectable Equals Untransmittable
por: Gunn, Jayleen K. L., et al.
Publicado: (2021)

Inflammatory biomarkers prior to antiretroviral therapy as prognostic markers of 12-month mortality in South Africa and Uganda
por: Siedner, Mark J., et al.
Publicado: (2019)

Prevalence and Outcomes of Hepatitis B Coinfection and Associated Liver Disease Among Antiretroviral Therapy-Naive Individuals in a Rural Tanzanian Human Immunodeficiency Virus Cohort
por: Ramírez-Mena, Adrià, et al.
Publicado: (2016)

Unsatisfactory long-term virological suppression in human immunodeficiency virus-infected children in the Amazonas State, Brazil
por: Pacheco, Ana Luisa Opromolla, et al.
Publicado: (2020)

Myocardial Fibrosis Among Antiretroviral Therapy-Treated Persons With Human Immunodeficiency Virus in South Africa
por: Shuldiner, Scott R, et al.
Publicado: (2020)

Antiretroviral Refill Histories as a Predictor of Future Human Immunodeficiency Virus Viremia
por: Sokpa, Darryl, et al.
Publicado: (2022)

Detection of HIV Virologic Failure and Switch to Second-Line Therapy: A Systematic Review and Meta-analysis of Data From Sub-Saharan Africa
por: Bernabé, Kerlly J, et al.
Publicado: (2022)

The Effect of Hepatitis C Virologic Clearance on Cardiovascular Disease Biomarkers in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection
por: Chew, Kara W., et al.
Publicado: (2014)

Long-Term Virological Treatment Outcomes in Adolescents and Young Adults With Perinatally and Non-Perinatally Acquired Human Immunodeficiency Virus
por: Weijsenfeld, Annouschka M, et al.
Publicado: (2022)

Changes in Immune Activation During Pregnancy and the Postpartum Period in Treated HIV Infection
por: Schnittman, Samuel R, et al.
Publicado: (2021)

Factors Associated With Liver Steatosis in People With Human Immunodeficiency Virus on Contemporary Antiretroviral Therapy
por: Riebensahm, Carlotta, et al.
Publicado: (2022)

Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis
por: De Castro, Nathalie, et al.
Publicado: (2022)

Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study
por: Brooks, Kristina M, et al.
Publicado: (2020)

Virologic Failure and Human Immunodeficiency Virus Drug Resistance in Rural Cameroon With Regard to the UNAIDS 90-90-90 Treatment Targets
por: Boullé, Charlotte, et al.
Publicado: (2016)

Assessment of Noninvasive Markers of Steatosis and Liver Fibrosis in Human Immunodeficiency Virus-Monoinfected Patients on Stable Antiretroviral Regimens
por: Busca, C, et al.
Publicado: (2022)

Cryptococcal Antigenemia in Nigerian Patients With Advanced Human Immunodeficiency Virus: Influence of Antiretroviral Therapy Adherence
por: Oladele, Rita O., et al.
Publicado: (2016)

Cost-Effectiveness of Preemptive Switching to Efavirenz-Based Antiretroviral Therapy for Children With Human Immunodeficiency Virus
por: Desmonde, Sophie, et al.
Publicado: (2019)

Impact of Pharmacist-Driven Antiretroviral Stewardship and Transitions of Care Interventions on Persons With Human Immunodeficiency Virus
por: Brizzi, Marisa B, et al.
Publicado: (2020)

Virologic Outcomes Among People Living With Human Immunodeficiency Virus With High Pretherapy Viral Load Burden Initiating on Common Core Agents
por: Mills, Anthony M, et al.
Publicado: (2021)

Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort
por: Elvstam, Olof, et al.
Publicado: (2022)

Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I
por: Gregson, J, et al.
Publicado: (2020)

Optimal Timing of Antiretroviral Therapy Initiation in Children and Adolescents With Human Immunodeficiency Virus-Associated Pulmonary Tuberculosis
por: Kay, Alexander, et al.
Publicado: (2022)

Impact of Integrase Inhibitors on Cardiovascular Disease Events in People With Human Immunodeficiency Virus Starting Antiretroviral Therapy
por: Surial, Bernard, et al.
Publicado: (2023)

Antiretroviral Initiation at ≥800 CD4+ Cells/mm(3) Associated With Lower Human Immunodeficiency Virus Reservoir Size
por: Rasmussen, Thomas A, et al.
Publicado: (2022)

Impact of Multicomponent Support Strategies on Human Immunodeficiency Virus Virologic Suppression Rates During Coronavirus Disease 2019: An Interrupted Time Series Analysis
por: Spinelli, Matthew A, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_prcmofps9qv4mo2cac0s4rkktp